Find News

Filter articles

Applied Filters

Showing 181 to 190 of 1079 results

Teva charged in DoJ antitrust probe into generic drug price-fixing

US26-08-2020Legal developmentsMuireann Bolger

Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.

Intercept sues Apotex over Ocaliva generic

26-08-2020Rory O'Neill

Intercept Pharmaceuticals is suing Canadian generics manufacturer Apotex over a proposed version of autoimmune drug Ocaliva.

Judge allows Dr Reddy’s to add antitrust claims in Indivior dispute

US25-08-2020Sarah Morgan

A district judge has given India-based Dr Reddy’s the greenlight to move forward with its antitrust counterclaims against Indivior. 

Mylan launches Tecfidera generic amid Biogen battle

US20-08-2020Sarah Morgan

Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.

FDA approves Dr Reddy’s Vascepa generic

US13-08-2020Rory O'Neill

Indian drugmaker Dr Reddy’s has won approval to launch just the second generic version of heart drug Vascepa, in another blow for Amarin.

Teva sues Cipla over generic asthma inhalers

11-08-2020Rory O'Neill

Israeli drug manufacturer Teva Pharmaceuticals is suing India-based Cipla to block the launch of generic Qvar asthma inhalers.

BMS, Pfizer secure victory over generic makers

US07-08-2020Sarah Morgan

In a victory for Bristol-Myers Squibb and Pfizer, a US federal judge has affirmed patents covering blood-thinner Eliquis.

Humira buyers appeal AbbVie ruling to Seventh Circuit

US31-07-2020Sarah Morgan

Buyers of AbbVie’s arthritis treatment Humira have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.

Ninth Circuit affirms California’s pay-for-delay ban

US27-07-2020Rory O'Neill

A US federal appeals court has refused to block California’s ban on pay-for-delay deals in the generic drugs industry.

Sun Pharma to pay $205m over generics price-fixing

24-07-2020Rory O'Neill

A subsidiary of India’s Sun Pharma has agreed to pay more than $200 million to settle charges related to a generics price-fixing investigation.

Showing 181 to 190 of 1079 results